highly significantP =7.03 × 10 −3
The reduced proliferation signature could stratify stage I patients in two groups with highly significant differences in prognosis ( Figure 3B : HR=5.92; 95% CI: 1.62–21.59; P =7.03 × 10 −3 Wald test).
The reduced proliferation signature could stratify stage I patients in two groups with highly significant differences in prognosis ( Figure 3B : HR=5.92; 95% CI: 1.62–21.59; P =7.03 × 10 −3 Wald test).